Achilles Therapeutics will design therapies to target truncal tumor neo-antigens—unique flags to the immune system present on the surface of every cancer cell, which were first discovered by Cancer Research UK and the NIHR University College London Hospitals (UCLH) Biomedical Research Centre (BRC) funded scientists at the Francis Crick Institute and UCL Cancer Institute.
Truncal tumor neo-antigens are present on all cancer cells in an individual patient’s tumor but not on healthy cells, so could allow scientists to target and destroy tumors without harming healthy tissues.
Syncona and CRT, with the support of UCL Business (UCLB) and the Crick, formed Achilles Therapeutics with a successful financing round of £13.2 million ($17.5 million) led by Syncona with the CRT Pioneer Fund and the UCL Technology Fund.
The company founders bring together world-class capability from three prestigious institutions. They are:
Professor Charles Swanton, Group Leader and Royal Society Napier Professor at the Francis Crick Institute and UCL Cancer Institute working on cancer evolution and genome instability and a consultant at UCLH
Professor Karl Peggs, Group Leader of the Stem Cell Transplantation and Cellular Immunotherapy Group at UCL Cancer Institute and a consultant at UCLH
Dr Sergio Quezada, Group Leader of the Immune Regulation and Tumour Immunotherapy Group at UCL Cancer Institute
Professor Mark Lowdell, Director of the Centre for Cell, Gene & Tissue Therapeutics at the Royal Free Hospital.
CRT will receive equity milestones and royalties from products developed and commercialized by Achilles Therapeutics. Any such financial reward from the company will be shared with UCLB and the Crick.
The company has exclusive rights to develop and commercialize neo-antigen technologies arising from Cancer Research UK’s £14million TRACERx study. This clinical study, involving 850 people with non-small cell lung cancer, tracks the evolution of patients’ cancers over time, in different parts of their tumors and in response to treatment. It receives infrastructure support from the NIHR University College London Hospitals BRC and is being carried out at the Clinical Research Facility at UCLH.
Professor Charles Swanton, scientific founder of Achilles Therapeutics and a Group Leader at the Francis Crick Institute, said, “Our research could provide a truly personalized approach to lung cancer therapy by targeting cell surface markers that are specific to each patient and present on all cancer cells rather than just a subset of cells. We’re delighted to be able to bring this exciting science closer to the clinic. We hope to create a new and kinder treatment for this hard-to-treat disease that results in around 36,000 patient deaths each year in the U.K.”
Iraj Ali, Partner with Syncona LLP and Director of Achilles Therapeutics, said, “In founding Achilles we believe we are working with the world leaders capable of exploiting the confluence of two of the most exciting and innovative fields in healthcare today: cancer bioinformatics and immuno-therapy. Our ambition is to build a company to deliver personalized therapies with transformative potential for cancer patients with the greatest need.”
Chris Ashton, CEO of Achilles Therapeutics, said, “This company is underpinned by world-leading science, committed investors and leading health institutes. Bringing all of these major players together holds great promise for non-small cell lung cancer patients and I hope that working alongside one another we will see great successes in the future.”
